PRAL and coronary artery disorder: RCS analysis showed a linear dose-response relationship between elevated PRAL and severe CAD risk (P-for-overall-trend = 0.0176; P-for-nonlinearity = 0.1552), and a nonlinear association between higher NEAP and increased severe CAD risk (P-for-overall-trend = 0.0001; P-for-nonlinearity = 0.006).